Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

NCT05335473 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

87

Enrollment

OTHER_GOV

Sponsor class

Conditions

HR Positive HER2 Negative Advanced Breast Cancer

Interventions

DRUG: Eribulin and Tucidinostat

Sponsor

Henan Cancer Hospital